Cargando…
Relationship between CYP3A5 Polymorphism and Tacrolimus Blood Concentration Changes in Allogeneic Hematopoietic Stem Cell Transplant Recipients during Continuous Infusion
A polymorphism in the gene encoding the metabolic enzyme cytochrome P450 family 3 subfamily A member 5 (CYP3A5) is a particularly influential factor in the use of tacrolimus in Japanese patients. Those who are homozygotic for the *3 mutation lack CYP3A5 activity, which results in substantial individ...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8070336/ https://www.ncbi.nlm.nih.gov/pubmed/33920149 http://dx.doi.org/10.3390/ph14040353 |
_version_ | 1783683446189588480 |
---|---|
author | Yoshikawa, Naoki Takeshima, Hidemi Sekine, Masaaki Akizuki, Keiichi Hidaka, Tomonori Shimoda, Kazuya Ikeda, Ryuji |
author_facet | Yoshikawa, Naoki Takeshima, Hidemi Sekine, Masaaki Akizuki, Keiichi Hidaka, Tomonori Shimoda, Kazuya Ikeda, Ryuji |
author_sort | Yoshikawa, Naoki |
collection | PubMed |
description | A polymorphism in the gene encoding the metabolic enzyme cytochrome P450 family 3 subfamily A member 5 (CYP3A5) is a particularly influential factor in the use of tacrolimus in Japanese patients. Those who are homozygotic for the *3 mutation lack CYP3A5 activity, which results in substantial individual differences in tacrolimus metabolism. The aim of this study was to analyze the relationship between individual differences in tacrolimus blood concentration changes and CYP3A5 polymorphisms in allogeneic hematopoietic stem cell transplantation recipients during the period of increasing blood concentration of the drug following treatment onset. This was a prospective observational cohort study, involving 20 patients administered tacrolimus by continuous infusion. The subjects were divided into the *1/*3 and *3/*3 groups based on CYP3A5 polymorphism analysis. The tacrolimus blood concentration/dose (C/D) ratio increased from day 1 and was largely stable on day 5, and a significant difference was observed between the *1/*3 and *3/*3 groups in the time course of the C/D ratio during this period (p < 0.05). This study reveals the effects of CYP3A5 polymorphism on continuous changes in tacrolimus blood concentration. |
format | Online Article Text |
id | pubmed-8070336 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80703362021-04-26 Relationship between CYP3A5 Polymorphism and Tacrolimus Blood Concentration Changes in Allogeneic Hematopoietic Stem Cell Transplant Recipients during Continuous Infusion Yoshikawa, Naoki Takeshima, Hidemi Sekine, Masaaki Akizuki, Keiichi Hidaka, Tomonori Shimoda, Kazuya Ikeda, Ryuji Pharmaceuticals (Basel) Article A polymorphism in the gene encoding the metabolic enzyme cytochrome P450 family 3 subfamily A member 5 (CYP3A5) is a particularly influential factor in the use of tacrolimus in Japanese patients. Those who are homozygotic for the *3 mutation lack CYP3A5 activity, which results in substantial individual differences in tacrolimus metabolism. The aim of this study was to analyze the relationship between individual differences in tacrolimus blood concentration changes and CYP3A5 polymorphisms in allogeneic hematopoietic stem cell transplantation recipients during the period of increasing blood concentration of the drug following treatment onset. This was a prospective observational cohort study, involving 20 patients administered tacrolimus by continuous infusion. The subjects were divided into the *1/*3 and *3/*3 groups based on CYP3A5 polymorphism analysis. The tacrolimus blood concentration/dose (C/D) ratio increased from day 1 and was largely stable on day 5, and a significant difference was observed between the *1/*3 and *3/*3 groups in the time course of the C/D ratio during this period (p < 0.05). This study reveals the effects of CYP3A5 polymorphism on continuous changes in tacrolimus blood concentration. MDPI 2021-04-10 /pmc/articles/PMC8070336/ /pubmed/33920149 http://dx.doi.org/10.3390/ph14040353 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Yoshikawa, Naoki Takeshima, Hidemi Sekine, Masaaki Akizuki, Keiichi Hidaka, Tomonori Shimoda, Kazuya Ikeda, Ryuji Relationship between CYP3A5 Polymorphism and Tacrolimus Blood Concentration Changes in Allogeneic Hematopoietic Stem Cell Transplant Recipients during Continuous Infusion |
title | Relationship between CYP3A5 Polymorphism and Tacrolimus Blood Concentration Changes in Allogeneic Hematopoietic Stem Cell Transplant Recipients during Continuous Infusion |
title_full | Relationship between CYP3A5 Polymorphism and Tacrolimus Blood Concentration Changes in Allogeneic Hematopoietic Stem Cell Transplant Recipients during Continuous Infusion |
title_fullStr | Relationship between CYP3A5 Polymorphism and Tacrolimus Blood Concentration Changes in Allogeneic Hematopoietic Stem Cell Transplant Recipients during Continuous Infusion |
title_full_unstemmed | Relationship between CYP3A5 Polymorphism and Tacrolimus Blood Concentration Changes in Allogeneic Hematopoietic Stem Cell Transplant Recipients during Continuous Infusion |
title_short | Relationship between CYP3A5 Polymorphism and Tacrolimus Blood Concentration Changes in Allogeneic Hematopoietic Stem Cell Transplant Recipients during Continuous Infusion |
title_sort | relationship between cyp3a5 polymorphism and tacrolimus blood concentration changes in allogeneic hematopoietic stem cell transplant recipients during continuous infusion |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8070336/ https://www.ncbi.nlm.nih.gov/pubmed/33920149 http://dx.doi.org/10.3390/ph14040353 |
work_keys_str_mv | AT yoshikawanaoki relationshipbetweencyp3a5polymorphismandtacrolimusbloodconcentrationchangesinallogeneichematopoieticstemcelltransplantrecipientsduringcontinuousinfusion AT takeshimahidemi relationshipbetweencyp3a5polymorphismandtacrolimusbloodconcentrationchangesinallogeneichematopoieticstemcelltransplantrecipientsduringcontinuousinfusion AT sekinemasaaki relationshipbetweencyp3a5polymorphismandtacrolimusbloodconcentrationchangesinallogeneichematopoieticstemcelltransplantrecipientsduringcontinuousinfusion AT akizukikeiichi relationshipbetweencyp3a5polymorphismandtacrolimusbloodconcentrationchangesinallogeneichematopoieticstemcelltransplantrecipientsduringcontinuousinfusion AT hidakatomonori relationshipbetweencyp3a5polymorphismandtacrolimusbloodconcentrationchangesinallogeneichematopoieticstemcelltransplantrecipientsduringcontinuousinfusion AT shimodakazuya relationshipbetweencyp3a5polymorphismandtacrolimusbloodconcentrationchangesinallogeneichematopoieticstemcelltransplantrecipientsduringcontinuousinfusion AT ikedaryuji relationshipbetweencyp3a5polymorphismandtacrolimusbloodconcentrationchangesinallogeneichematopoieticstemcelltransplantrecipientsduringcontinuousinfusion |